Skip to main content

Table 1 Basic characteristics of patients receiving OAT in 2014 and 2017 in Sweden and Norway

From: Uptake and predictors of direct-acting antiviral treatment for hepatitis C among people receiving opioid agonist therapy in Sweden and Norway: a drug utilization study from 2014 to 2017

  2014 2017
Country Sweden Norway Sweden Norway
OAT studypopulation, n 2663 6057 2739 5545
Gender, n (%)
 Male 1911 (72) 4266 (70) 1961 (72) 3870 (70)
 Female 752 (28) 1791 (30) 778 (28) 1675 (30)
Age, n (%)
 18–35 671 (25) 1219 (20) 647 (24) 878 (16)
 36–45 817 (31) 2181 (36) 819 (30) 1747 (32)
 46–55 744 (28) 2044 (34) 713 (26) 1998 (36)
 56–75 431 (16) 613 (10) 560 (20) 922 (17)
Mean age (SD)
 Male 44 (10) 44.1 (9) 45.1 (11) 46.1 (9)
 Female 43.5 (11) 43.1 (9) 44.3 (12) 45.2 (10)
OAT medication, n (%)a
 Methadone/levomethadone 1267 (48) 2810 (46) 1198 (44) 2504 (45)
 Buprenorphine 875 (33) 2049 (34) 1075 (39) 2190 (40)
 Buprenorphine/naloxone 521 (20) 1198 (20) 466 (17) 851 (15)
  1. Sources: The Swedish Prescribed Drug Register (SPDR), The Norwegian Prescription Database (NorPD)
  2. OAT Opioid agonist therapy, SD Standard deviation
  3. aLast registered OAT medication each calendar year